Retrospective	0	13	O
case	14	18	O
series	19	25	O
of	26	28	O
juxtafoveal	29	40	O
choroidal	41	50	O
neovascularization	51	69	O
treated	70	77	O
with	78	82	O
photodynamic	83	95	O
therapy	96	103	O
with	104	108	O
verteporfin	109	120	B-Drug_or_compound
.	120	121	O

PURPOSE	123	130	O
:	130	131	O
To	132	134	O
describe	135	143	O
visual	144	150	O
acuity	151	157	O
and	158	161	O
angiographic	162	174	O
outcomes	175	183	O
of	184	186	O
juxtafoveal	187	198	O
choroidal	199	208	O
neovascularization	209	227	O
(	228	229	O
CNV	229	232	O
)	232	233	O
treated	234	241	O
with	242	246	O
photodynamic	247	259	O
therapy	260	267	O
and	268	271	O
verteporfin	272	283	B-Drug_or_compound
(	284	285	O
PDT	285	288	O
)	288	289	O
.	289	290	O

METHODS	291	298	O
:	298	299	O
Four	300	304	O
hundred	305	312	O
eighty	313	319	O
-	319	320	O
four	320	324	O
consecutive	325	336	O
eyes	337	341	B-Organ
of	342	344	O
446	345	348	O
patients	349	357	B-Organism
treated	358	365	O
with	366	370	O
PDT	371	374	O
from	375	379	O
January	380	387	O
1	388	389	O
,	389	390	O
2001	391	395	O
,	395	396	O
to	397	399	O
June	400	404	O
30	405	407	O
,	407	408	O
2002	409	413	O
,	413	414	O
were	415	419	O
identified	420	430	O
from	431	435	O
billing	436	443	O
records	444	451	O
.	451	452	O

Fluorescein	453	464	B-Drug_or_compound
angiograms	465	475	O
were	476	480	O
reviewed	481	489	O
retrospectively	490	505	O
to	506	508	O
identify	509	517	O
juxtafoveal	518	529	O
CNV	530	533	O
.	533	534	O

Eligible	535	543	O
patients	544	552	B-Organism
had	553	556	O
CNV	557	560	O
in	561	563	O
which	564	569	O
the	570	573	O
central	574	581	O
boundary	582	590	O
of	591	593	O
the	594	597	O
lesion	598	604	B-Pathological_formation
was	605	608	O
between	609	616	O
1	617	618	O
and	619	622	O
199	623	626	O
microm	627	633	O
from	634	638	O
the	639	642	O
geometric	643	652	O
center	653	659	O
of	660	662	O
the	663	666	O
foveal	667	673	B-Tissue
avascular	674	683	I-Tissue
zone	684	688	I-Tissue
(	689	690	O
FAZ	690	693	B-Tissue
)	693	694	O
.	694	695	O

Patient	696	703	B-Organism
charts	704	710	O
were	711	715	O
reviewed	716	724	O
for	725	728	O
visual	729	735	O
acuity	736	742	O
of	743	745	O
the	746	749	O
treated	750	757	O
eye	758	761	B-Organ
before	762	768	O
PDT	769	772	O
and	773	776	O
at	777	779	O
6	780	781	O
-	781	782	O
and	783	786	O
12	787	789	O
-	789	790	O
month	790	795	O
follow	796	802	O
-	802	803	O
up	803	805	O
examinations	806	818	O
.	818	819	O

Presence	820	828	O
of	829	831	O
subfoveal	832	841	O
CNV	842	845	O
at	846	848	O
6	849	850	O
and	851	854	O
12	855	857	O
months	858	864	O
of	865	867	O
follow	868	874	O
-	874	875	O
up	875	877	O
was	878	881	O
determined	882	892	O
by	893	895	O
review	896	902	O
of	903	905	O
fluorescein	906	917	B-Drug_or_compound
angiograms	918	928	O
.	928	929	O

A	930	931	O
lesion	932	938	B-Pathological_formation
was	939	942	O
considered	943	953	O
subfoveal	954	963	O
if	964	966	O
it	967	969	O
extended	970	978	O
underneath	979	989	O
the	990	993	O
geometric	994	1003	O
center	1004	1010	O
of	1011	1013	O
the	1014	1017	O
FAZ	1018	1021	B-Tissue
.	1021	1022	O

RESULTS	1023	1030	O
:	1030	1031	O
Twenty	1032	1038	O
-	1038	1039	O
one	1039	1042	O
eyes	1043	1047	B-Organ
had	1048	1051	O
juxtafoveal	1052	1063	O
CNV	1064	1067	O
.	1067	1068	O

Median	1069	1075	O
change	1076	1082	O
in	1083	1085	O
visual	1086	1092	O
acuity	1093	1099	O
both	1100	1104	O
6	1105	1106	O
and	1107	1110	O
12	1111	1113	O
months	1114	1120	O
after	1121	1126	O
the	1127	1130	O
initial	1131	1138	O
PDT	1139	1142	O
was	1143	1146	O
0	1147	1148	O
lines	1149	1154	O
(	1155	1156	O
n	1156	1157	O
=	1158	1159	O
18	1160	1162	O
at	1163	1165	O
6	1166	1167	O
months	1168	1174	O
,	1174	1175	O
range	1176	1181	O
-	1182	1183	O
14	1183	1185	O
to	1186	1188	O
+	1189	1190	O
8	1191	1192	O
lines	1193	1198	O
;	1198	1199	O
n	1200	1201	O
=	1202	1203	O
17	1204	1206	O
at	1207	1209	O
12	1210	1212	O
months	1213	1219	O
,	1219	1220	O
range	1221	1226	O
-	1227	1228	O
18	1228	1230	O
to	1231	1233	O
+	1234	1235	O
7	1236	1237	O
lines	1238	1243	O
)	1243	1244	O
.	1244	1245	O

Eleven	1246	1252	O
lesions	1253	1260	B-Pathological_formation
progressed	1261	1271	O
to	1272	1274	O
a	1275	1276	O
subfoveal	1277	1286	O
location	1287	1295	O
by	1296	1298	O
12	1299	1301	O
months	1302	1308	O
.	1308	1309	O

Visual	1310	1316	O
acuity	1317	1323	O
in	1324	1326	O
eyes	1327	1331	B-Organ
with	1332	1336	O
progressive	1337	1348	O
lesions	1349	1356	B-Pathological_formation
decreased	1357	1366	O
a	1367	1368	O
median	1369	1375	O
of	1376	1378	O
4	1379	1380	O
lines	1381	1386	O
of	1387	1389	O
vision	1390	1396	O
.	1396	1397	O

CONCLUSIONS	1398	1409	O
:	1409	1410	O
Despite	1411	1418	O
a	1419	1420	O
small	1421	1426	O
sample	1427	1433	O
size	1434	1438	O
and	1439	1442	O
limited	1443	1450	O
length	1451	1457	O
of	1458	1460	O
follow	1461	1467	O
-	1467	1468	O
up	1468	1470	O
,	1470	1471	O
this	1472	1476	O
study	1477	1482	O
shows	1483	1488	O
that	1489	1493	O
visual	1494	1500	O
acuity	1501	1507	O
on	1508	1510	O
average	1511	1518	O
can	1519	1522	O
remain	1523	1529	O
stable	1530	1536	O
for	1537	1540	O
at	1541	1543	O
least	1544	1549	O
12	1550	1552	O
months	1553	1559	O
after	1560	1565	O
PDT	1566	1569	O
of	1570	1572	O
juxtafoveal	1573	1584	O
lesions	1585	1592	B-Pathological_formation
.	1592	1593	O

Growth	1594	1600	O
through	1601	1608	O
the	1609	1612	O
foveal	1613	1619	B-Tissue
center	1620	1626	I-Tissue
still	1627	1632	O
can	1633	1636	O
occur	1637	1642	O
,	1642	1643	O
however	1644	1651	O
,	1651	1652	O
and	1653	1656	O
this	1657	1661	O
can	1662	1665	O
be	1666	1668	O
associated	1669	1679	O
with	1680	1684	O
substantial	1685	1696	O
visual	1697	1703	O
loss	1704	1708	O
.	1708	1709	O

